Steven Shak

University of North Carolina at Chapel Hill — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

65h-index40.8kcitations218works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(110), HER2/EGFR in Cancer Research(44), Advanced Breast Cancer Therapies(41), Cancer Genomics and Diagnostics(34), Cancer Treatment and Pharmacology(23)

Publications218 total

Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial
UNC Libraries·2025Open Access
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
JNCI Journal of the National Cancer Institute·2024· 8 citedOpen Access
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer
Journal of Clinical Oncology·2024· 8 cited
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.
UNC Libraries·2024Open Access
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival
NEJM Evidence·2024· 12 citedOpen Access
Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.
Journal of Clinical Oncology·2024· 1 cited
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).
Journal of Clinical Oncology·2024· 16 cited
Updated SEER database study of 21-gene assay to assess breast cancer–specific mortality and benefit of chemotherapy by race and ethnicity.
Journal of Clinical Oncology·2024
Abstract PO1-02-02: Update of RSClin with extended TAILORx follow-up and development and validation of a new tool for risk of late distant recurrence
Cancer Research·2024
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
Journal of Clinical Oncology·2023· 154 cited
Supplementary Table 3 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure 1 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table 3 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
2023Open Access
Supplementary Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
2023Open Access
Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
2023Open Access
Supplementary Figure 2 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table 1 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
2023Open Access
Data from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure 2 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure 1 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Frederick L. Baehner(17), Norman Wolmark(13), Joffre Baker(12), Drew Watson(12), Soonmyung Paik(11), Gong Tang(9), Maureen Cronin(8), D. Lawrence Wickerham(8), Joseph P. Costantino(8), Dennis J. Slamon(6), Melody Cobleigh(6), Louis Fehrenbacher(6), Charles E. Geyer(6), Charles L. Vogel(5), Debu Tripathy(5), Eleftherios P. Mamounas(5), Kim M. Clark-Langone(5), Virginia Paton(4), Chungyeul Kim(4), Michael G. Walker(4)